Abcam, ab223574, Anti-LCAT antibody

Size: 100µg
Goat Polyclonal LCAT antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human LCAT aa 350-400.
Key facts
Host species:Goat,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human LCAT aa 350-400. The exact immunogen used to generate this antibody is proprietary information.P04180

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Purification notes-ab223574 was purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide., Storage buffer-pH: 7.3Preservative: 0.02% Sodium azideConstituents: Tris buffered saline, 0.5% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LCAT also known as lecithin-cholesterol acyltransferase is an enzyme with a molecular mass of approximately 68 kDa. It belongs to the family of esterases and is mainly expressed in the liver. LCAT circulates in the bloodstream playing a significant role in lipid metabolism by catalyzing the formation of cholesteryl esters from free cholesterol and phosphatidylcholine (lecithin) on the surface of high-density lipoproteins (HDL).
Biological function summary
This enzyme functions centrally in the maturation of high-density lipoprotein particles. LCAT interacts with and acts upon HDL converting nascent HDL into mature HDL by catalyzing the esterification of cholesterol. This process results in the sequestration of cholesterol within the core of HDL particles essential for reverse cholesterol transport to the liver. Moreover LCAT does not operate as part of a larger complex but is an active enzyme on its own within various lipid transport processes.
Pathways
LCAT's action significantly influences the lipid metabolism and reverse cholesterol transport pathways. In the lipid metabolism pathway it works closely with apolipoproteins such as apoA-I which serves as an activator. ApoA-I stabilizes the enzymatic action of LCAT promoting cholesterol homeostasis whereas LCAT ensures the efficient transfer of cholesterol to the liver within the reverse cholesterol transport pathway contributing to the maintenance of lipid balance.
LCAT deficiency can lead to conditions like familial LCAT deficiency and Fish Eye disease. These disorders are marked by abnormal cholesterol and lipid accumulation due to impaired LCAT activity. Apolipoproteins particularly apoA-I also demonstrate a significant connection as mutations or lack of apoA-I compromise LCAT activation exacerbating hyperlipidemia and related lipid disorders.